Drug Trial Radar · NCT03662126
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Last checked: Nov 19, 2026Latest source record: Apr 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
385
Planned (sponsor's estimate)
Start
Jan 15, 2019
Primary completion
Dec 31, 2023
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Kartos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive either KRT-232 (Arm 1) or BAT (Arm 2). The BAT administered will be determined by the treating physician, with the option to "cross-over" to KRT-232 treatment after 6 months of BAT or if the disease worsens at any time.
Conditions
- Primary Myelofibrosis (PMF)
- Post-Polycythemia Vera MF (Post-PV-MF)
- Post-Essential Thrombocythemia MF (Post-ET-MF)
Interventions
KRT-232Drug
KRT-232, administered by mouth
Best Available Therapy (BAT)Drug
Best available therapy options include: 1. hydroxyurea 2. chemotherapy or 3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Part A Only) Spleen Volume Reduction (SVR)Time frame: 24 weeks
- (Part B Only) Spleen Volume Reduction (SVR)Time frame: 24 Weeks
Locations
191 sites in 28 countries. Site status is shown where the registry gives one.
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama · Active not recruiting
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California · Active not recruiting
Stanford Cancer Center - Palo Alto
Stanford, California · Active not recruiting
Innovative Clinical Research Institute
Whittier, California · Completed
University Cancer Institute
Boynton Beach, Florida · Withdrawn
Northwestern University Feinberg School of Medicine
Chicago, Illinois · Completed
University of Illinois at Chicago
Chicago, Illinois · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Withdrawn
Washington University School of Medicine
St Louis, Missouri · Recruiting
Brookdale University Hospital and Medical Center
Brooklyn, New York · Recruiting
New York Presbyterian/Weill Cornell Medical Center
New York, New York · Withdrawn
Mt. Sinai
New York, New York · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Completed
Oregon Health and Science University
Portland, Oregon · Completed
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Medical College of Wisconsin - Froedtert Hospital
Milwaukee, Wisconsin · Recruiting
Instituto Medico Alexander Fleming
Buenos Aires, Argentina · Recruiting
Centro Medico San Luis
CABA, Argentina · Recruiting
Hospital Privado - Centro Medico de Cordoba - Oncology
Córdoba, Argentina · Recruiting
Sanatorio de la Mujer
Rosario, Santa Fe Province, Argentina · Recruiting
Royal Adelaide Hospital
Adelaide, Australia · Recruiting
The Alfred Hospital
Melbourne, Australia · Recruiting
South Eastern Private Hospital
Noble Park, Australia · Recruiting
Icon Cancer Center
South Brisbane, Australia · Recruiting
Monash Medical Centre
Clayton, Victoria, Australia · Recruiting
Fiona Stanley Hosital
Murdoch, Western Australia, Australia · Recruiting
Hospital das Clínicas UFG
Goiânia, Brazil · Recruiting
Fundacao Doutor Amaral Carvalho
Jaú, Brazil · Recruiting
Hospital de Clinicas de Porto Alegre - Centro de Pesquisa Clinica
Porto Alegre, Brazil · Recruiting
Associação Educadora São Carlos AESC - Hospital Mãe de Deus - Centro de Pesquisa
Porto Alegre, Brazil · Recruiting
Instituto de Ensino e Pesquisa São Lucas
São Paulo, Brazil · Recruiting
Hospital A C Camargo - Fundacao Antonio Prudente
São Paulo, Brazil · Recruiting
Instituto D'or de Pesquisa e Ensino
São Paulo, Brazil · Recruiting
Hospital das Clínicas da Universidade de São Paulo
São Paulo, Brazil · Recruiting
Instituto COI São Paulo
São Paulo, Brazil · Recruiting
Centro de oncologia Leonardo da Vinci
Fortaleza, Ceará, Brazil · Recruiting
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil · Recruiting
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.